20th MEET THE PROFESSOR

Advanced International Breast Cancer Course

Padova | October 24-25, 2024
Centro Culturale S. Gaetano Altinate

Presentation

Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 20th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

Gynecologists and obstetrics
Medical oncologists
Pathologists

Radiologists
Radiation oncologists
Surgeons

Biologists
Pharmacists
Nurses

Scientific Program

Thursday, October 24th

10:30

Introduction to the Conference
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly

11.00	Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas Alberto Zambelli
11.20	The immune system and breast cancer: TNBC and beyond Marleen Kok
11.40	DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer Mafalda Oliveira
12.00	Tackling the biological diversity in HER2-positive breast cancer: clinical implications Aleix Prat
12.20	Discussion
12.50	Lunch

SESSION II – LOCOREGIONAL Tx AND GENOMICS

Chairpersons: Eleftherios Mamounas, Jacek Jassem

14.00	Surgery of the axilla: is less always more? Oreste Davide Gentilini
14.20	Navigating RT options according to genetic risck profiles Philip Poortmans
14.40	Evolving concepts in genetic testing: finding the balance Angela Toss
15.00	Discussion

SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY

Chairpersons: Pierfranco Conte, Johannes Holtschmidt

15.30	Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+ (pert, TDM1, neratinib,trials) Johannes Holtschmidt
15.50	Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC (IO, PARPi, capecitabine) Pierfranco Conte
16.10	Indication to and modalities of neoadjuvant Tx in HR+HER2- BC Valentina Guarneri
16.30	Discussion
17.00	Adjourn
17.15	Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2024
17.30	Lecture of the Awardee
18.00	Adjourn

Friday, October 25th

SESSION IV – EARLY BREAST CANCER

Chairpersons: Valentina Guarneri, Aleix Prat

9.00	Enhancing efficacy of hormonal therapy in early breast cancer (bisphosphonates, extended, CDK4/6i, SERDs, PARPi…) Stephen Johnston
9.20	Optimizing treatment for small tumors depending on local treatments Hope Rugo
9.40	The challenge of lobular breast cancer Maria Vittoria Dieci
10.00	Discussion
10.30	Coffee break
11.00	Clinical Multidisciplinary Shooting Session 1 – Early Breast Cancer Panelist: Bettina Borisch, Hesham Ahmed Gaballah Elghazaly, Oreste Davide Gentilini, Johannes Holtschmidt, Jacek Jassem, Eleftherios Mamounas, Alberto Marchet, Fedro Alessandro Peccatori, Philip Poortmans, Aleix Prat
12.30	Lunch

SESSION V METASTATIC BREAST CANCER: CONSOLIDATED AND NEW ALGORITHMS

Chairpersons: Pierfranco Conte, Sandra Swain M

13.30	HR+ disease Current algorithm: Claudio Vernieri Adapting the algorithm in a contemporary scenario: Carmen Criscitiello
14.00	HER2+ disease Current algorithm: Federica Miglietta Treatment sequences in new emerging populations: Sandra Swain
14.30	Triple negative disease Current algorithm: Gaia Griguolo Treatment sequences in new emerging populations: Hope Rugo
15.00	Discussion
15.20	Clinical Multidisciplinary Shooting Session 2 – Advanced Breast Cancer Panelist: Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly, Oreste Davide Gentilini, Stephen Johnston, Philip Poortmans, Hope Rugo, Sandra Swain M
16.40	Take home messages and adjourn Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat